Because all of the SCD-high lines were sensitive and the SCD-low lines were resistant, our data demonstrate that at least in GBM and perhaps other human cancers, SCD expression could be a determining factor during patient selection for SCD inhibitor therapy. The gene discussed is SCD; the disease is glioblastoma.